Abstract:
:Approximately 25% of breast cancer patients without lymph node metastases develop systemic relapse. A growing body of data supports the notion that hematogenous dissemination of breast cancer cells occurs independently of lymphatic spread of disease; however, current clinical practice does not involve routine analysis of circulating or disseminated cells. Recent studies have documented that both circulating tumor cells (CTCs) within the blood and disseminated tumor cells (DTCs) in bone marrow can be identified using a variety of techniques. It is now clear that the presence of DTCs correlates with subsequent development of clinically evident bone metastases, and a worse outcome from breast cancer. While there are data identifying prognostic significance of CTCs in patients with metastatic breast cancer, there are few data regarding CTCs in operable patients. Factors such as presence of a cancer stem cell phenotype and/or certain microenvironmental conditions are involved in the establishment of distant metastases from a primary breast cancer, emphasizing the need for further studies within this area. The purpose of this report is to review the data regarding CTCs and DTCs in patients with operable breast cancer.
journal_name
Expert Rev Anticancer Therjournal_title
Expert review of anticancer therapyauthors
Lang JE,Hall CS,Singh B,Lucci Adoi
10.1586/14737140.7.10.1463subject
Has Abstractpub_date
2007-10-01 00:00:00pages
1463-72issue
10eissn
1473-7140issn
1744-8328journal_volume
7pub_type
杂志文章,评审abstract::Radiation therapy is the backbone in the management of intracranial germinoma. In localized disease chemotherapy followed by whole brain irradiation is the present standard providing cure rates in excess of 90%. Craniospinal irradiation alone in metastatic disease provides equally excellent outcome. Chemotherapy is ab...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2014.856268
更新日期:2014-01-01 00:00:00
abstract::A recent population-based study on 2000 adult patients with Burkitt lymphoma presented a novel score that takes into account age, race and clinical stage to prognosticate survival. The outcome of patients with Burkitt lymphoma has improved in the last decade, likely due to intensive chemotherapy regimens and anti-CD20...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章
doi:10.1586/14737140.2014.866042
更新日期:2014-02-01 00:00:00
abstract::Atypical hyperplasia and lobular carcinoma in situ are rare proliferative breast lesions, growing inside ducts and terminal ducto-lobular units. They represent a marker of increased risk for breast cancer and a non-obligate precursor of malignancy. Evidence available on diagnosis and management is scarce. They are fre...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2016.1143362
更新日期:2016-01-01 00:00:00
abstract::Introduction: Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and the third largest cause of cancer-relateddeaths worldwide. Potentially curative treatments (surgical resection, radiofrequency or liver transplantation) are only available for few patients, while transarterial chemoembolizat...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章
doi:10.1080/14737140.2020.1712198
更新日期:2020-01-01 00:00:00
abstract:INTRODUCTION:Germ cell tumors (GCTs) are the most common solid malignancies in young men. The overall cure rate of GCT patients in metastatic stage is excellent, however; patients with relapsed or refractory disease have poor prognosis. Attempts to treat refractory disease with novel effective treatment to improve prog...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章
doi:10.1080/14737140.2021.1838279
更新日期:2020-11-02 00:00:00
abstract:INTRODUCTION:Although a relatively uncommon disease, the treatment of vulvar cancer has changed considerably over the years and has been under considerable focus due to its past overtreatment and apparent increase in incidence. The purpose of this review is to describe the recommended management of the most commonly en...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1080/14737140.2019.1538797
更新日期:2019-01-01 00:00:00
abstract::Malignant gliomas are the most prevalent type of primary brain tumor in adults. Despite progress in brain tumor therapy, the prognosis of malignant glioma patients remains dismal. The median survival of patients with glioblastoma multiforme, the most common grade of malignant glioma, is 10-12 months. Conventional ther...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.6.7.1087
更新日期:2006-07-01 00:00:00
abstract::Defined by its high level of accuracy and rapid radiation dose fall-off, radiosurgery has emerged as an effective radiation technique over the past few decades. Although it was once limited to conditions of the brain, head and neck regions, technological advances in computing and imaging have allowed the application o...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.7.11.1507
更新日期:2007-11-01 00:00:00
abstract:INTRODUCTION:Dysfunction of the immune system is a hallmark of cancer. Through increased understanding of the complex interactions between immunity and cancer, immunotherapy has emerged as a treatment modality for different types of cancer. Promising activity with immunotherapy has been reported in numerous malignancie...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章
doi:10.1080/14737140.2021.1865814
更新日期:2021-01-19 00:00:00
abstract::Although testicular cancer is currently a rare disease, the incidence is rising. The most important risk factor remains cryptorchism and there is a variable association with testicular microlithiasis. Serum tumor markers remain important for diagnosis, and they have prognostic value and can be used to monitor therapy ...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.4.4.669
更新日期:2004-08-01 00:00:00
abstract::Primary systemic therapy (PST) in early breast cancer is utilized in locally advanced breast tumors and when breast-conserving surgery is desirable. In addition, the PST setting provides an opportunity to monitor response including histopathological and biomarker examination of the tumor and host tissues before and af...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.12.62
更新日期:2012-08-01 00:00:00
abstract::With the introduction of orally-active, potent and selective third-generation aromatase inhibitors and inactivators--anastrozole, letrozole and exemestane--approaches to the treatment of advanced breast cancer are undergoing re-evaluation. In advanced breast cancer, aromatase inhibitors and inactivators are likely to ...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2.3.267
更新日期:2002-06-01 00:00:00
abstract::The association between venous thromboembolism (VTE) and malignancy was first recognized more than 135 years ago. Since then, a markedly increased incidence of VTE has been found in patients with malignant disease. Numerous clinical studies have demonstrated that malignancy or its treatment are major risk factors for ...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.4.2.303
更新日期:2004-04-01 00:00:00
abstract::As diagnostic and therapeutic options increase, strategies for the treatment of non-small-cell lung cancer (NSCLC) are becoming more tailored for specific patient subpopulations and individual patients. The introduction of therapy targeted against the EGF receptor (EGFR) pathway has provided new treatment options for ...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.10.104
更新日期:2010-10-01 00:00:00
abstract::miRNAs, which are small single-stranded RNA molecules composed of 18-23 nts, act as oncogenes or tumor suppressor genes playing important roles in the processes of tumor formation, infiltration and metastasis. Lung cancer currently has the highest morbidity and mortality among all malignant tumors; yet, lack of early ...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2013.870037
更新日期:2014-04-01 00:00:00
abstract::Cardiac toxicity is one of the most important long-term toxicities experienced by cancer survivors so that survival rate due to anticancer therapy may be negatively affected due to cardiac complications. Thus, the search for novel methods to lower the incidence of treatment-related cardiotoxicity is a priority for all...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2015.1047766
更新日期:2015-01-01 00:00:00
abstract:INTRODUCTION:Mutations in BRCA1 and BRCA2 genes account for around 2-3% of breast cancer events and more than 10% of triple negative breast cancers. Olaparib (Lynparza®), an orally administered PARP inhibitor, demonstrated clinical benefit in a phase III trial for mutated BRCA-positive HER2 negative metastatic breast c...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1080/14737140.2018.1458613
更新日期:2018-06-01 00:00:00
abstract::Head and neck cancer is the fifth most common cancer in the USA. Although there have been major improvements in surgical and radiation techniques, the overall survival has not changed significantly in the last decade. The major changes occurring in recent years have been in the ability to preserve organs and to improv...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.8.4.633
更新日期:2008-04-01 00:00:00
abstract::Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. With combined modality treatment long-term survival rate for localized disease is near 70%. Thirty percent of patients relapse with lung as the commonest site. Surgery is the treatment of choice for relapsed patients whenever pos...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2014.863453
更新日期:2014-02-01 00:00:00
abstract::Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of these patients and is considered the standard of care. Nevertheless, 40-50% of patients have impaired renal function that p...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/era.10.197
更新日期:2011-06-01 00:00:00
abstract::Hematopoietic stem cell transplantation is an effective treatment for patients with relapsed or refractory Hodgkin lymphoma. Treatment outcome is better among patients who demonstrate sensitivity to salvage chemotherapy. Approximately half of the patients undergoing autologous stem cell transplantation will be cured a...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.7.3.297
更新日期:2007-03-01 00:00:00
abstract::Adrenocortical carcinoma is a rare disorder with a prevalence of one case per 1.7 million people and a generally poor prognosis. It accounts for 0.02% of all cancer cases and 0.2% of cancer deaths. Within the past three decades, accurate diagnosis, precise radiologic localization, satisfactory preoperative medical man...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.7.9.1295
更新日期:2007-09-01 00:00:00
abstract::Therapeutic outcomes of the currently used chemotherapeutic agents for recurrent or advanced head and neck squamous cell carcinoma, such as methotrexate or a combination of 5-fluorouracil and cisplatin, are far beyond satisfaction. New chemotherapeutic agents, such as taxanes, paclitaxel and docetaxel, are among the m...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.1.1.99
更新日期:2001-06-01 00:00:00
abstract::Small cell carcinoma of the urinary bladder (SCCUB) is a rare and aggressive disease. To date, no standard treatment has been proposed due to the lack of prospective studies resulting from the rarity of this disease. Recently published studies of relatively large patient cohorts, however, have shed some light on the m...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.2013.851605
更新日期:2013-11-01 00:00:00
abstract::The development of consensus classifications for renal epithelial neoplasia in 1996 and 1997 led to the recognition of renal adenoma, renal oncocytoma and metanephric adenoma/adenofibroma as benign tumors and conventional (clear cell) renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and collecting duct carci...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.1.4.576
更新日期:2001-12-01 00:00:00
abstract::Ovarian cancer frequently presents late, when chances for long-term survival are poor. The increased survival advantage for patients diagnosed with early-stage ovarian cancer suggests that screening to detect early-stage disease might have an impact on disease mortality. Attempts are being made to develop effective sc...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.3.1.55
更新日期:2003-02-01 00:00:00
abstract::The annual conference of the International Society for Biological Therapy of Cancer (iSBTc), recently renamed the Society for Immunotherapy of Cancer (SITC), provides clinicians and scientists with a uniquely broad yet focused view of the growing field of tumor immunology and cancer immunotherapy. In this time of exci...
journal_title:Expert review of anticancer therapy
pub_type:
doi:10.1586/era.10.229
更新日期:2011-03-01 00:00:00
abstract:INTRODUCTION:In the recent years, melanoma patients' outcome and survival improved, mainly because of systemic treatment improvement with targeted therapy and checkpoint blockade. Targeted therapy with BRAF and MEK inhibitors was approved to treat patients with unresectable or metastatic melanoma, harboring BRAF V600 m...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1080/14737140.2016.1192469
更新日期:2016-07-01 00:00:00
abstract::Nonmelanoma skin cancer is the most prevalent malignant disease among light-skinned individuals in the USA, accounting for approximately 1 million new cases annually. Solar ultraviolet radiation is known to be the major cause of skin cancer. The idea that diet, particularly dietary fat, may play a role in modulating c...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1586/14737140.5.5.801
更新日期:2005-10-01 00:00:00
abstract:INTRODUCTION:Hormone receptor positive (HR+) breast cancer represents the most common subtype of breast cancer. Metastatic HR+ breast cancer may develop resistance to standard hormone therapies, arising from genomic alterations in the estrogen receptor and/or upregulation of other signal transduction pathways. Areas co...
journal_title:Expert review of anticancer therapy
pub_type: 杂志文章,评审
doi:10.1080/14737140.2018.1412259
更新日期:2018-01-01 00:00:00